Gene targets of antisense therapies in breast cancer

Bibliography

• STEEG PS, CLARE SE, LAWRENCE JA,ZHOU Q: Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Am. j Pathol. (1996) 149:733–738.
   PubMed Web of Science ®Google Scholar
• DUBIK D, WATSON PH, VENDITTI M,SHIU RP: Nuclear oncogenes in breast cancer. Cancer Treat. Res. (1996) 83:171–189.
   Google Scholar
• GOLDMAN R, SHIELDS PG: Molecularepidemiology of breast cancer. In vivo (1998) 12:43–48.
   Google Scholar
• SLAMON DJ, CLARK GM, WONG SG, LEVINE WJ, ULLRICH A, MCGUIRE WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235:177–182.
   PubMed Web of Science ®Google Scholar
• TSUTSUI S, OHNO S, MURAKAMI S, HACHITANDA Y, ODA S: Prognostic value of c-erbB2 expression in breast cancer. Sorg. arca (2002) 79:216–223.
   Google Scholar
• RAIT AS, PIROLLO KF, RAIT V, KRYGIER JE, XIANG L, CHANG EH: Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer. Cancer Gene Ther. (2001) 8:728–739.
   Google Scholar
• ROH H, PIPPIN JA, GREEN DW et al: HER2/neu antisense targeting of human breast carcinoma. Oricogerre (2000) 19:6138–6143.
   Google Scholar
• SUZUKI T, ANDEREGG B, OHKAWA T et al.: Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther. (2000) 7:241–248.
   PubMed Web of Science ®Google Scholar
• WANG H, CAI Q, ZENG X, YU D, AGRAWAL S, ZHANG R: Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the Rla subunit of protein kinase A after oral administration. Proc. Nati Acad. Li. USA (1999) 96:13989–13994.
   PubMed Web of Science ®Google Scholar
• RU K, SCHMITT S, JAMES WI, WANG JH: Growth inhibition and antimetastatic effect of antisense poly-DNP-RNA on human breast cancer cells. arca Res. (1999) 11:505–512.
   Google Scholar
• TORTORA G, CAPUTO R, DAMIANO V et al.: Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc. Natl. Acad. Sci. USA (1997) 94:12586–12591.
   Google Scholar
• RUBENSTEIN M, MIROCHNIK Y, CHOU E GUINAN P: Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides. Methods Paid Exp. Clirr. Pharmacol. (1998) 20:825–831.
   Google Scholar
• DIXIT M, YANG JL, POIRIER MC, PRICE JO, ANDREWS PA, ARTEAGA CL: Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J. Natl. Cancer Inst. (1998) 89:341–343.
   Google Scholar
• CAMMILLERI S, SANGRAJRANG S, PERDEREAU B et al.: Biodistribution of iodine-125 tyramine transforming growth factor alpha antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injection. Eur. J Nucl. Med. (1996) 23:448–452.
   Google Scholar
• WU RS, KOBIE JJ, BESSELSEN DG et al.:Comparative analysis of IFN-y B7.1 and antisense TGF-I3 gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immurrol. Immunothemphy (2001) 50:229–240.
   Google Scholar
• KUMMAR S, ISHII A, YANG HK, VENZON DJ, KIM SJ, GRESS RE: Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-PI. Biol. Blood Marrow Transplant. (2001) 7:25–30.
   Google Scholar
• PARK JA, WANG E, KURT RA, SCHLUTER SF, HERSH EM, AKPORIAYE ET: Expression of an antisense transforming growth factor-I31 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther (1997) 4:42–50.
   PubMed Web of Science ®Google Scholar
• CHERNICKY CL, YI L, TAN H, GAN SU, ILAN J: Treatment of human breast cancer cells with antisense RNA to the Type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther. (2000) 7:384–395.
   PubMedGoogle Scholar
• TURNER BC, HAFFTY BG, NARAYANAN L etal.: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. (1997) 57:3079–3083.
   Google Scholar
• NEUENSCHWANDER S, ROBERTS CT JR, LEROITH D: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth Factor I receptor antisense ribonucleic acid. Endocrinology (1995) 136:4298–4303.
   PubMed Web of Science ®Google Scholar
• UPADHYAY S, NEBURI M, CHINNI SR, ALHASAN S, MILLER F, SARKAR FH: Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21 (WAF1). Chu. Cancer Res. (2001) 7:1782–1789.
   PubMed Web of Science ®Google Scholar
• WANG H, NAN L, YU D, AGRAWAL S, ZHANG R: Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Chu. Cancer Res. (2001) 7:3613–3624.
   PubMed Web of Science ®Google Scholar
• HUSAIN A, HE G, VENKATRAMAN ES, SPRIGGS DR: BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res. (1998) 58:1120–1123.
   PubMed Web of Science ®Google Scholar
• GAUTSCHI 0, TSCHOPP S, OLIE RA et al.: Activity of a novel Bc1-2/Bc1-xL-bispecific antisense oligonucleotideagainst tumors of diverse histologic origins.Natl. Cancer Inst. (2001) 93:463–471.
   Google Scholar
• BANERJEE D: Genasense (Genta Inc). Cun: Opiri. Investig. Drugs (2001) 2:574–580.
   Google Scholar
• GIANNIOS J, GINOPOULOS P: Induction of PCD in tamoxifen-resistant estrogen receptor positive (ER+) advanced breast cancer after combined therapy with ER antisense oligonucleotides and vinorelbine-tartrate encapsulated in DRV liposomes. Eur. j Cancer (2000) 36\(Suppl. 4):103.
   Google Scholar
• IM SA, KIM JS, GOMEZ-MANZANO C, FUEYO J et al.: Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGE Br j Cancer (2001) 84:1252–1257.
   Google Scholar
• GOTTESMAN MM, FOJO T, BATES SE: Multidrug resistance in cancer: role of ATP dependent transporters. Nature Rev Cancer (2002) 2:48–58.
   PubMed Web of Science ®Google Scholar
• JAROSZEWSKI JW, KAPLAN 0, SYI JL, SEHESTED M, FAUSTINO PJ, COHEN JS: Concerning antisense inhibition of the multiple drug resistance gene. Cancer Commun. (1990) 2:287–294.
   Google Scholar
• WANG E JIANG XI YANG DC, ELLIOTT RL, HEAD JF: Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res. (2000) 20:799–808.
   Google Scholar
• THIERRY AR, DRITSCHILO A: Liposomal delivery of antisense oligodeoxynucleotides. Application to the inhibition of the multidrug resistance in cancer cells. Ann. NY Acad. Sci. (1992) 660:300–302.
   Google Scholar
• AHMAD S, GLAZER RI: Expression of theantisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol. Pharmacol. (1993) 43:858–862.
   PubMed Web of Science ®Google Scholar
• YANG DC, WANG E ELLIOTT RL, HEAD JF: Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res. (2001) 21:541–549.
   PubMed Web of Science ®Google Scholar
• YANG DC, JIANG XI ELLIOTT RL, HEAD JF: Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide target to the transferring receptor gene. Anticancer Res. (2001) 21:177–187.
   Google Scholar
• YANG DC, JIANG XI ELLIOTT RL, HEAD JF: Inhibition of growth of human breast carcinoma cells by antisense oligonucleotides targeted to the ferritin genes. Anticancer Res. (In press).
   Google Scholar
• LIZ, XIA W, FANG B, YAN DH: Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression. Cancer Lett. (2001) 174:151–158.
   Google Scholar
• ARTEAGA CL, HOLT JT: Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res. (1996) 56:1098–1103.
   Google Scholar
• HOLT JT, ARTEAGA CB, ROBERTSON D, MOSES HL: Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA. Hum. Gene Ther. (1996) 7:1367–1380.
   Google Scholar
• MAIRESSE N, HORMAN S, MOSSELMANS R, GALAND P: Antisense inhibition of the 27 kDa heat shock protein production affects growth rate and cytoskeletal organization in MCF-7 cells. Cell Biol. Int. (1996) 20:205–212.
   PubMed Web of Science ®Google Scholar
• GEIGER T, MULLER M, MONIA BE FABBRO D: Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subscutaneously into nude mice. Chu. Cancer Res. (1997) 3:1179–1185.
   PubMed Web of Science ®Google Scholar
• WATSON PH, PON RT, SHIU RP: Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. (1991) 51:3996–4000.
   PubMed Web of Science ®Google Scholar
• KUSHNER DM, SILVERMAN RH: Antisense cancer therapy: the state of the science. Curr. Oricol. Rep. (2000) 2:23–30.
   Google Scholar
• GEWIRTZ AM: Oligonucleotide therapeutics: clothing the emperor. Curr. Opiri. Mol. Ther. (1999) 1:297–306.
   PubMedGoogle Scholar
• ABDEL-MAGEED A, AGRAWAL KC: Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Cerie Ther. (1997) 4:199–207.
   Google Scholar
• COLEMAN J, GREEN P, INOUYE M: The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes. Cell (1984) 37:429–436.
   PubMed Web of Science ®Google Scholar
• CROWLEY TE, NELLEN W, GOMER RH, FIRTEL RA: Phenocopy of discoidin I-minus mutants by antisense transformation in Dictyostelium. Cell (1985) 43:633–641.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, IKEUCHI T, SUN D etal.: Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues. Proc. Nati Acad. Sri. USA (1989) 86:7790–7794.
   Google Scholar
• GOODCHILD J, AGRAWAL S, CIVERIA MP, SARIN PS, SUN D, ZAMECNIK PC: Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc. Nati Acad. Sri. USA (1988) 85:5507–5511.
   PubMed Web of Science ®Google Scholar
• MOSEER HE, DERVAN PB: Sequence-specific cleavage of double helical DNA by triple helix formation. Science (1987) 238:645–650.
   Google Scholar
• PERROUAULT L. ASSELINE U, RIVALLE C etal.: Sequence-specific artificial photo-induced endonucleases based on triple helix-forming oligonucleotides. Nature (1990) 344:358–360.
   Google Scholar
• PORUMB H, GOUSSET H, LETELLIER R et al: Temporary ex vivo inhibition of the expression of the human oncogene HER-2 (NEU) by a triple helix-forming oligonucleotide. Cancer Res. (1996) 56:515–522.
   Google Scholar
• HELENE C, MONTENAY-GARESTIER T, SAISON T etal.: Oligodeoxynucleotides covalently linked to intercalating agents: a new class of gene regulatory substances. Bloch:Mite (1985) 67:777–783.
   Google Scholar
• CHENG X, DELONG RK, WICKSTROM E et al: Interactions between single-stranded DNA binding protein and oligonucleotide analogs with different backbone chemistries. j Mai Recognit. (1997) 10:101–107.
   Google Scholar
• GEWIRTZ AM: Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications. Mt. Sinai j Med. (1996) 63:372–380.
   Google Scholar
• CHU BC, ORGEL LE: Inhibition of DNA synthesis by cross-linking the template to platinum-thiol derivatives of complementary oligodeoxynucleotides. Nucleic Acid Res. (1989) 17:4783–4798.
   Google Scholar
• WANG LX, YANG DC, LU YY et al.: The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends. Drug Des. Biscay. (1995) 13:109–121.
   Google Scholar
• BOIDOT-FORGET M, CHASSIGNOL M, TAKASUGI M, THUONG NT, HELENE C: Site-specific cleavage of single-stranded and double-stranded DNA sequences by oligodeoxynucleotides covalently linked to an intercalating agent and EDTA-Fe chelate. Gene (1988) 72:361–371.
   PubMed Web of Science ®Google Scholar
• COREY DR, PEI D, SCHULTZ PG: Generation of a catalytic sequence-specific hybrid DNase. Biochemistry (1989) 28:8277–8286.
   Google Scholar
• JIANG WG, GRIMSHAW D, LANE J et al.: A hammerhead ribozyme suppress expression of hepatocyte growth factor/ scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. GM Cancer Res. (2001) 7:2555–2562.
   Google Scholar
• HOLT JT, ARTEGA CB, ROBERTSON D, MOSES HL: Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA. Hum. Gene Ther (1996) 7:1367–1380.
   Google Scholar
• SUZUKI T, ANDEREGG B, OHKAWA T etal.: Adenovirus-mediated ribozyme targeting of HER2/neu inhibits in vivo growth of breast cancer cells. Gene Ther (2000) 7:241–248.
   Google Scholar
• PODSAKOFF G, WONG la JR, CHATTERJEE S: Efficient gene transfer into nondividing cells by adeno-associated virus-bases vectors. j Viral. (1994) 68:5656–5666.
   PubMed Web of Science ®Google Scholar
• ANDREANSKY SS, HE B, GILLESPIE GY et at The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Nati Acad. Sri. USA (1996) 93:11313–11318.
   PubMed Web of Science ®Google Scholar
• BERGAN R, HAKIM F, SCHWARTZ GN et al.: Electroporation of synthetic oligonucleotides: a novel technique for ex vivo bone marrow purging. Blood(1996) 88:731–741.
   PubMed Web of Science ®Google Scholar
• MONTEITH DK, LEVIN AA: Synthetic oligonucleotides: the development of antisense therapeutics. Taxical. Pathol. (1999) 27:8–13.
   PubMed Web of Science ®Google Scholar
• FLAHERTY KT, STEVENSON JP, O'DWYER PJ: Antisense therapeutics: lessons from early clinical trials. Curr. Opin. arca (2001) 13:499–505.
   Google Scholar
• WRAIGHT CJ, WHITE PJ: Antisense oligonucleotides in cutaneous therapy. Pharmacal. Ther (2001) 90:89–104.
   PubMed Web of Science ®Google Scholar